

Zeitschrift: Acta Tropica
Herausgeber: Schweizerisches Tropeninstitut (Basel)
Band: 23 (1966)
Heft: (9): Thérapeutique nouvelle de la Bilharziose et de l'amibiase :
Symposium de Lisbonne 2 au 4 Juin 1965

Artikel: Treatment of "Schistosomiasis mansoni" with a new nitrothiazole
derivative, CIBA 32644-Ba
Autor: Prata, Aluizio / Machado, Ruy / Macedo, Vanize
DOI: <https://doi.org/10.5169/seals-311373>

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. [Mehr erfahren](#)

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. [En savoir plus](#)

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. [Find out more](#)

Download PDF: 20.08.2025

ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>

Treatment of *Schistosomiasis mansoni* with a New nitrothiazole Derivative, CIBA 32644-Ba

ALUIZIO PRATA *, RUY MACHADO *, and VANIZE MACEDO *

CUCKLER, KUPFERBERG and MILLMAN (2) demonstrated that certain nitrothiazole derivatives have activity against schistosomes. These investigators treated *Schistosoma mansoni* infection in mice and demonstrated that 2-acetamido-5-nitrothiazole killed most of the adult worms and inhibited egg production in the worms that remained alive. However, 2-amino-5-nitrothiazole was completely ineffective. AMATO NETO and PRATA (1) treated 10 patients with 2-acetamido-5-nitrothiazole in a dose of 600 mg daily for 10 days. Although the drug was well tolerated, all of the patients continued to pass stool positive for ova of *S. mansoni*.

1-(5-nitro-2-thiazolyl)-2-imidazolidinone (CIBA 32644-Ba) was synthesized by WILHELM and SCHMIDT (3). The chemistry, pharmacology and activity against *S. mansoni* have been determined, and some preliminary clinical trials have been completed (3, 4, 5, 6).

The purpose of this paper is to present preliminary results in the treatment of human schistosomiasis with CIBA 32644-Ba.

Materials and Methods

Ten patients were treated with CIBA 32644-Ba in January, 1965 and 35 were treated in May, 1965. All of the patients were males, 16-19 years of age, who were attending the Naval School in Bahia, Brazil. There were 11 whites, 25 mulattoes and 9 negroes. They were restricted to the grounds of the school on weekdays and were free to leave only at weekends. The admission requirements for the school include a complete physical examination and all of the men had been found to be in good health.

The patients ranged in height from 161-182 cm and from 45 to

* Hospital das Clinicas, Dept. of Tropical Medicine, Salvador/Bahia, Brazil.

TABLE 1

Symptomatology before treatment in 45 patients

Patients	Occasional complaints
4	Asthenia, anorexia, diarrhoea
5	Headache, heartburn
6	Diarrhoea
7	Diarrhoea, streaks of blood in the stools, dyspepsia
8	Asthenia, light-headedness, diarrhoea, nausea, abdominal pain
9	Diarrhoea
14	Light-headedness. Fatty food intolerance
16	Hemicrania
17	Diarrhoea
18	Epistaxis
19	Diarrhoea
20	Anorexia, tonsillitis
21	Streaks of blood in the stools
28	Diarrhoea
29	Diarrhoea, streaks of blood in the stools, dyspepsia
30	Light-headedness
33	Headache
34	Headache, diarrhoea, abdominal pain
37	Constipation
38	Dysentery
40	Diarrhoea, streaks of blood in the stools, abdominal pain
42	Asthenia, light-headedness
43	Asthenia, light-headedness
Twenty-two patients had no symptoms	

68 kg in weight. The liver was enlarged in only one patient and was felt 4 cm below the right costal margin. The spleen was palpable in three patients only on deep inspiration.

All of the patients had ova of *S. mansoni* in the stool. The incidence of other ova in the stool was *Ascaris lumbricoides* 98%, *Trichuris trichiura* 93%, hookworm 77% and *Strongyloides stercoralis* 27%. Twenty-two of the 45 patients were asymptomatic and the other 23 complained of the symptoms listed in Table 1.

The patients were divided into the following four groups:

- I. Patients 1-10 who received CIBA 32644-Ba in a dose of 30 mg/kg daily for 10 days in January, 1965.
- II. Patients 11-20 who received 20 mg/kg for 5 days in May, 1965.
- III. Patients 21-30 who received 30 mg/kg for 10 days in May, 1965.
- IV. Patients 31-45 who received 40 mg/kg for 5 days in May, 1965.

The drug was taken by mouth, two times a day (before breakfast and before supper) in the presence of a nurse. The patients continued their normal daily activities during the period of treat-

ment and each day they were questioned for manifestations of toxicity.

Group I had the following laboratory examinations before and after therapy: haemoglobin, red blood cell count, white blood cell count and differential, urine analysis, cephalin flocculation test, thymol turbidity and thymol flocculation. The other groups had daily determinations of weight, pulse rate and axillary temperature during therapy; urine analysis before and after; non-protein nitrogen determinations after; and electrocardiograms during and after completion of treatment.

Rectal biopsies were performed on five different patients each day during the second to eighth days of therapy, and 16 days after initiation of treatment in order to determine the time of cessation of oviposition in the rectum and the effect of CIBA 32644-Ba on the ova.

An evaluation of cure could be made only in Group I and consisted of 4-16 examinations of stool for ova performed 2-4 months after completion of therapy, and one rectal biopsy done 4 months after completion of therapy.

Results

Table 2 demonstrates the results of serial rectal biopsies. Ova of the first stage began to diminish in number after the third day of therapy and disappeared completely from the rectal wall after the fifth day. It is of interest that during the initial days of therapy small, deformed and infertile eggs were present in the rectal biopsies. Rectal biopsies performed on the sixteenth day after initiation of therapy revealed few mature viable ova but immature ova were not present.

Only Group I has been followed long enough to evaluate results of therapy. As demonstrated in Table 3, 7 of the 10 patients have continued to have stools free of ova of *S. mansoni*. In 3 patients ova of *S. mansoni* reappeared in the stool 57, 75 and 76 days after completion of therapy.

Table 4 lists the toxicity and side effects of the drug. The most common side effects were headache, asthenia, anorexia, abdominal pain, light-headedness, nausea, vomiting and diarrhoea. These symptoms were minor and appeared after the second or third day. It is important to note that generalized convulsions occurred on the fifth day of therapy in two patients who were receiving a daily dose of 40 mg/kg of CIBA 32644-Ba. These patients each had 2 typical epileptiform seizures.

TABLE 2

Disappearance of immature eggs during treatment with CIBA 32644-Ba
(5 rectal biopsies each day)

Days of treatment	First Stage		Second Stage		Third Stage		Fourth Stage		Mature	
	Positive biopsies	Total eggs	Positive biopsies	Total eggs	Positive biopsies	Total eggs	Positive biopsies	Total eggs	Positive biopsies	Total eggs
1	—	—	—	—	—	—	—	—	—	—
2	3	45	4	126	4	58	0	0	5	51
3	1	35	2	47	2	2	1	2	4	55
4	0	0	1	20	3	12	1	1	5	104
5	1	5	1	6	2	25	1	1	3	34
6	0	0	1	1	3	35	0	0	3	116
7	0	0	3	3	4	22	4	30	5	201
8	0	0	0	0	1	2	0	0	2	35

TABLE 3

Stool examinations and rectal biopsy following therapy

Patient	Stool Examinations																			Rectal Biopsy
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
1	—	+	+	+	—	+	+	—	—	+	—	+	+	+	+					—
2	—	—	—	—																—
3	—	—	—	—	—	—	+	+	+	—	—	—	—	—						—
4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—			—
5	—	—	—	—	—	—	—	—	—	—	—	—	—	—						—
6	—	—	—	—																—
7	—	—	—	—	—	—	—	—	—	—	+	—	+	—	—	—	—	—	—	—
8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—			—
9	—	—	—	—	—	—	—	—	—	—										—
10	—	—	—	—	—	—	—	—	—	—	—	—								—

TABLE 4

Toxicity and side-effects with CIBA 32644-Ba

Manifestations	Daily dose per kg		
	20 mg	30 mg	40 mg
	10 patients n.	20 patients n.	15 patients n.
Headache	2	10	7
Abdominal pain	3	6	6
Light-headedness	2	4	8
Nausea	1	8	4
Vomiting	1	2	4
Anorexia	1	9	0
Excess salivation	0	2	2
Constipation	0	2	0
Asthenia	0	8	1
Convulsions	0	0	2
Diarrhoea	0	1	2
Increase in appetite	0	1	0
Heartburn	1	0	0
Sore throat	1	3	0
Somnolence	0	1	0
Bitter sensation in the mouth	0	1	0
No complaints	3	1	2

n = Number of patients

During the course of therapy, 19 of the 35 patients in Groups II, III, and IV had axillary temperatures of 37°C or higher on at least one occasion. In one patient the temperature was elevated to 38°C. There was no abnormality in the pulse rate during therapy. Fourteen of the 35 patients lost weight and 13 gained weight during treatment. The maximum change in weight was 3 kg.

In the 10 patients in Group I, red blood cell counts and haemoglobin values were not altered by treatment. It is apparent that the total white blood cell count and the percentage of eosinophils increased during the course of therapy. The cephalin flocculation, thymol flocculation and thymol turbidity tests were not altered except in one patient in whom the cephalin flocculation changed from negative to 3+.

Soon after the initiation of treatment the colour of the urine became red. During therapy traces of protein appeared in the urine of 8 of the 10 patients. There were 6 red blood cells per high-powered field in the urine of one of these patients and another had 50 white blood cells per high-powered field. Determinations of blood urea nitrogen were normal in these 8 patients.

Electrocardiograms performed during treatment on the 35 patients in Groups II, III, and IV demonstrated abnormalities in the T waves of 6 patients. Subsequent electrocardiograms have not yet been obtained. These electrocardiographic alterations were not related to the size of the daily dose of CIBA 32644-Ba.

Discussion

It has been demonstrated (7) that the duration of the first stage of ova of *S. mansoni* is only one day. In the present study ova of the first stage seen in rectal biopsies began to diminish in number after the third day of therapy and disappeared completely on the sixth day. Therefore eggs were not deposited after the fifth day of treatment. These time relationships closely resemble those observed in previous studies in which rectal biopsies were performed on patients receiving antimonylithium thiomalate (anthiomaline) (7).

The appearance of small, deformed and infertile ova in the rectal biopsies indicates that CIBA 32644-Ba damages the genital system of the worms. However it is clear that some ova already deposited can continue to develop normally despite administration of the drug. This fact was demonstrated by the presence of mature viable ova in biopsies taken 16 days after initiation of therapy.

CIBA 32644-Ba was relatively well tolerated in doses of 20 to 30 mg/kg per day. The side effects listed in Table 4 were not constant and were generally minor. However at a dose of 40 mg/kg generalized convulsions occurred in 2 of 15 patients on the fifth day of treatment. This serious toxic side effect was reversible as the seizures did not recur after the drug was discontinued. Similarly, toxic doses of CIBA 32644-Ba have been reported to cause convulsions in animals (3). Abnormalities in the electrocardiogram have been reported before in humans receiving CIBA 32644-Ba (4).

Although the drug appears to be effective in these preliminary studies, additional groups of patients must be treated to allow a more adequate evaluation. Other interesting lines of investigation are the effect of the drug on the central nervous system and on spermatogenesis in humans.

Summary

45 patients with *Schistosomiasis mansoni* were treated with CIBA 32644-Ba.

The doses were 20 mg, 30 mg or 40 mg/kg daily for 5 to 10 days. Deformed, infertile eggs appeared in rectal biopsies shortly after

initiation of therapy and oviposition stopped on the fifth day. However, some ova already deposited, continued to develop normally despite administration of the drug.

Ten patients have been followed for a period of four months. Seven apparently have been cured, but in three patients ova of *S. mansoni* reappeared in the stool.

CIBA 32644-Ba was relatively well tolerated in daily doses of 20-30 mg/kg per day. However, at a dose of 40 mg/kg generalized convulsions occurred in 2 of 15 patients.

This drug appears to be a large step forward in the therapy of schistosomiasis.

Résumé

45 malades infestés par *S. mansoni* ont été traités par le CIBA 32644-Ba. Les doses furent de 20, 30 ou 40 mg/kg/jour pendant 5 à 10 jours.

Des œufs altérés, stériles sont apparus tôt après le début du traitement dans les biopsies rectales et la ponte paraît arrêtée au 5^e jour de traitement. Cependant quelques œufs, déjà pondus avant le traitement, continuent de se développer normalement en dépit de l'administration médicamenteuse.

10 malades ont été suivis pendant 4 mois. 7 ont été trouvés apparemment guéris, mais chez 3 malades des œufs de *S. mansoni* sont réapparus dans les selles.

Le CIBA 32644-Ba a été relativement bien toléré aux doses de 20 à 30 mg/kg/jour ; à 40 mg/kg/jour cependant, des convulsions ont été observées chez 2 des 15 malades traités.

Le nouveau médicament paraît bien être un grand pas en avant dans le traitement de la schistosomiase à *S. mansoni*.

References

1. AMATO NETO, V. & PRATA, A. (1958). Tratamento da esquistossomose mansoni pelo 2-acetamido-5-nitrotiazol (não publicado).
2. CUCKLER, A.; KUPFERBERG, A. B. & MILLMAN, N. (1955). Chemotherapeutic and tolerance studies on amino-nitro-thiazoles. — *Antibiot. et Chemother.* 5, 540-550.
3. Introductory report on preparation CIBA 32644-Ba, a schistosomicidal and amoebicidal agent.
4. Introductory report on treatment of hepatic amoebiasis with CIBA 32644-Ba. First clinical trials.
5. LAMBERT, C. R. & FERREIRA DA CRUZ, F. S. (1965). Résultats du premier essai de traitement de la bilharziose vésicale par le CIBA 32644-Ba. — *Bull. O.M.S.* 32, 73-82.
6. LAMBERT, C. R. & STAUFFER, P. (1964). Chemotherapy of experimental *Schistosoma mansoni* infections with a nitrothiazole derivative, CIBA 32644-Ba. — *Ann. Trop. Med. Parasitology* 58, No. 3, 292.
7. PRATA, A. (1957). Biopsia retal na esquistossomose mansoni; bases e aplicações no diagnostico e tratamento. — Bahia, Faculdade de Medicina, pp. 107, Tese.